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Abstract
We investigated 18 HIV-negative patients with MDR-TB for M. tuberculosis (Mtb)- and PPD-specific CD4 T cell responses and
followed them over 6 months of drug therapy. Twelve of these patients were sputum culture (SC) positive and six patients
were SC negative upon enrollment. Our aim was to identify a subset of mycobacteria-specific CD4 T cells that would predict
time to culture conversion. The total frequency of mycobacteria-specific CD4 T cells at baseline could not distinguish
patients showing positive or negative SC. However, a greater proportion of late-differentiated (LD) Mtb- and PPD-specific
memory CD4 T cells was found in SC positive patients than in those who were SC negative (p = 0.004 and p = 0.0012,
respectively). Similarly, a higher co-expression of HLA-DR+Ki67+ on Mtb- and PPD-specific CD4 T cells could also discriminate
between sputum SC positive versus SC negative (p = 0.004 and p = 0.001, respectively). Receiver operating characteristic
(ROC) analysis revealed that baseline levels of Ki67+HLA-DR+ Mtb- and PPD-specific CD4 T cells were predictive of the time
to sputum culture conversion, with area-under-the-curve of 0.8 (p = 0.027). Upon treatment, there was a significant decline
of these Ki67+HLA-DR+ T cell populations in the first 2 months, with a progressive increase in mycobacteria-specific
polyfunctional IFNc+IL2+TNFa+ CD4 T cells over 6 months. Thus, a subset of activated and proliferating mycobacterial-
specific CD4 T cells (Ki67+HLA-DR+) may provide a valuable marker in peripheral blood that predicts time to sputum culture
conversion in TB patients at the start of treatment.
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Introduction
The tuberculosis (TB) epidemic in many parts of the world has
been greatly exacerbated in recent years, not only by the HIV co-
epidemic, but also by the rise in multidrug resistant (MDR) strains
of M. tuberculosis (Mtb). MDR-TB is defined by resistance to
rifampicin (RIF) and isoniazid (INH), the two most effective drugs
against TB and the backbone of standard short-course therapy
[1,2]. The quest for new pharmaceuticals to combat both drug
susceptible and resistant TB and expand treatment options for
patients with MDR-TB is a major challenge. At present, the
success of TB therapy is established by the risk of relapse within
the first 2 years after treatment, which necessitates long clinical
trials and extended follow-up of patients. Thus, to support clinical
trials and improve case management, early predictors of clinical
outcome that can serve as interim indicators of treatment response
are needed. The only currently accepted interim indicators are
sputum culture conversion after 2 months of standard therapy and
time to culture positivity at the start of treatment, which provides
an indicator of bacillary load [3–5]. However, culture-based
methods require 6–8 weeks for a result and are only appropriate
for patients who are sputum culture positive at baseline. To
address this clinical need, as well as to shorten the time required
for clinical trials of new TB drugs in the pipeline, extensive efforts
to discover early biomarkers of response to TB treatment are
currently underway [6–9].
The evaluation of candidate host immune biomarkers is a
particularly active area of research, which additionally can
contribute to our general understanding of the pathogenesis of
TB disease [10]. A number of investigators have examined
serodiagnostic markers in patients before and during TB
treatment, including inflammatory molecules, cytokines and
chemokines, as well as antibodies against Mtb proteins [10–12]
and the host blood transcriptome [13,14]. Others have assessed
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various immune cell populations in peripheral blood and
bronchoalveolar lavage [10,15,16]. Although several groups have
described associations between specific markers of T cell
activation/function and outcome of TB treatment, there is, as
yet, no consensus in the field about the most promising candidates.
Importantly, many of the reported studies have used cross-
sectional designs to identify candidate biomarkers that can
differentiate patients with active disease from individuals who
have successfully completed TB treatment or have latent TB
infection, rather than following patients prospectively. Moreover,
few studies have examined the generalizability of candidate
biomarkers for use in monitoring patients during treatment of
MDR-TB [17]. This is an important question, as rising rates of
MDR-TB are increasingly hampering TB control, particularly in
regions with high prevalence of TB and HIV [18] [19]. Moreover,
the specific issues associated with conducting randomized
controlled trials of drug regimens in MDR-TB patients support
the value of investigating interim markers of response to treatment
in this population [20].
As part of a prospective cohort study to investigate host factors
associated with delayed response to treatment and treatment
failure in patients with MDR-TB, we have carried out a pilot study
to examine T cell markers in 18 patients. Our goal was to correlate
specific T cell subsets in blood with bacillary (antigen) load, as
indicated by sputum culture (SC) positivity, and to investigate
changes in the relative frequencies and phenotypic characteristics
of mycobacteria-specific CD4 T cell subsets in patients responding
to TB treatment. Our results show that TB patients have highly
activated mycobacteria-specific CD4+ T cells, which become less
activated as patients respond to chemotherapy. Validation of our
findings in a larger group of patients, including those with drug
susceptible TB, may identify a host cellular phenotype that can
provide a useful early marker predictive of time to culture
conversion.
Materials and Methods
Study participants and sample collection
Participants (n = 18) were recruited at Sizwe Hospital, the
central MDR-TB referral hospital in Gauteng Province, South
Africa. The study cohort had a median age of 39 years (IQR: 26–
51 years) and a sex ratio of 13:5 male:female. All enrolled patients
were HIV negative. TB diagnosis was based on sputum culture;
diagnosis of MDR was based on phenotypic drug susceptibility
testing (DST by Bactec MGIT 960, Beckton Dickinson, Baltimore,
MD) and/or genotypic resistance by PCR (Line Probe Assay,
Hain Lifesciences). All study participants were diagnosed with
culture positive MDR-TB based on sputum specimens obtained at
a median of 57 days (IQR: 33–99 days) prior to admission to Sizwe
Hospital (Table S1). As part of the admission process, routine chest
X-ray (CXR) was performed. CXR films were reviewed by
physicians (who were not study investigators) and scored for
cavitation (no, single or multiple cavities; ,2, 2–4 or .4 cm
diameter) and extent of disease (0, ,50% or $50% of area
affected) in six zones, defined by the mediastinum and horizontal
lines through the 2nd and 4th anterior rib shadows [21]. Nine
patients showed cavitation and all had evidence of TB disease by
CXR (Table S1), with the exception of #16, who showed no
cavitation and no significant signs of disease except for a possible
right parahilar mass.
Of the 18 patients enrolled, 15 had a prior history of TB, two of
whom (#3 and #11) had previously been treated for MDR-TB
and were receiving second line drugs at the time of admission to
Sizwe Hospital. Thirteen patients were receiving short-course TB
chemotherapy (with or without streptomycin) at the time of
admission; two (#9 and #12) had been diagnosed with primary
MDR-TB after initiating short-course therapy for drug susceptible
TB and 11 were admitted after failing short-course therapy. Three
patients had been admitted with primary MDR-TB and were TB
treatment naı¨ve (Table 1). Upon admission to Sizwe, patients were
initiated on a standardized MDR-TB drug regimen, consisting of
kanamycin, ofloxacin, ethionamide, terizodone and pyrazinamide
[21]. This regimen was modified for individual patients on the
basis of DST results indicating resistance to any of these drugs and
for those with prior history of treatment for MDR-TB. Additional
adjustments in regimens were made, as needed, for patients
showing adverse reactions to specific drugs during the course of
treatment (Table S1).
Blood samples for the study were collected at enrollment upon
admission to Sizwe Hospital and then at 2, 4 and 6 months after
initiating MDR-TB therapy. Peripheral blood was obtained in
sodium heparin Vacutainer tubes (BD Biosciences, San Diego,
CA, USA).
Ethics Statement
All study participants gave written, informed consent for the
study, which was approved by the Research Ethics Committees of
the Universities of the Witwatersrand (HREC protocol M090357)
and Cape Town and the Institutional Review Board of the
University of Medicine and Dentistry of New Jersey.
Reagents and antibodies
QuantiFERON-TB Gold tubes consisting of a Negative control
(Nil antigen); Mtb tube (containing of a cocktail of ESAT-6, CFP-
10 and TB7.7(p4) peptides); Mitogen (Mito) tube, (containing
phytohaemagglutinin (PHA) as the positive control) were obtained
from Cellestis Inc. (Valencia, CA, USA) and used in the whole
blood intracellular cytokine (ICS) assay. Tuberculin purified
protein derivative (PPD) was obtained from the Staten Serum
Institute (Copenhagen, Denmark) and used as a separate stimulus
at 10 mg/ml in the whole blood ICS assay. The following
fluorescently conjugated mAbs were used in this study: anti-CD8
V500 (RPA-T8), anti–IFNc Alexa Fluor 700 (B27), anti-TNFa
PEcy7 (MAb11), anti-Ki-67 FITC (B56) and anti-IL2 PE (MQ1-
17H12), all from BD Biosciences (San Diego, CA, USA); anti-CD3
Brilliant Violet 650 (Okt3) from Biolegend (San Diego, CA, USA)
anti-CD4 PEcy5.5 (S3.5) from Invitrogen (Grand Island, NY,
USA), anti-CD45RA ECD (2H4) from Beckman Coulter (Brea,
CA, USA); anti-CD27 PEcy5 (323) and anti-HLA-DR APC-
eFluor780 (LN3) from eBioscience (Wembley, UK).
12 hour-Whole blood ICS assay
Within a maximum of 45 min after blood collection, 1 ml of
sodium heparinized blood was incubated with PPD (10 mg/ml) or
added to the QuantiFERON-TB Gold tubes in the presence of
anti-CD28 (1 mg/ml, BD Pharmingen) and anti-CD49d (1 mg/ml,
BD Pharmingen) for 7 hrs at 37uC. Blood incubated in the
QuantiFERON-Nil Gold tube served as a negative control, and
blood incubated in the QuantiFERON-Mitogen Gold tube as a
positive control. After 7 hrs, brefeldin A (10 mg/ml; Sigma-
Aldrich, Dorset, UK) was added, and the incubation continued
for an additional 5 hrs [22]. Following the 12 hrs incubation,
2 mM EDTA was added for 10 min, then RBC were lysed and
white blood cells were fixed with FACS Lysing Solution (BD
Biosciences), followed by cryopreservation in freezing medium
containing 10% DMSO and stored in liquid nitrogen until use.
Cryopreserved cells were thawed, washed in PBS, permeabilized
with Perm/Wash solution (BD Biosciences). Cells were stained
Mycobacteria-Specific CD4 T Cells in MDR-TB Clearance
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with a panel of conjugated mAbs, described above, for 45 min at
4uC, washed in Perm/Wash Buffer (BD Biosciences), and
resuspended in PBS containing 1% formaldehyde, prior to
acquisition on an LSRII flow cytometer (BD Biosciences). At least
1.5 million total events were acquired for each sample.
Flow cytometry data analysis
Multiple-parameter flow cytometry data were analyzed using
FlowJo software (v9.5.3; Tree star Inc., Ashland, OR, USA). The
gating strategy is presented in Figure S1. Combinations of
cytokine-producing cells were determined using Boolean gating
in FlowJo, followed by further analysis using Pestle v1.6.2 and
Spice v5.3 (Dr. Mario Roederer, Vaccine Research Center,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, MD, USA). Cytokine responses
were considered positive when the frequency of total cytokine-
producing CD4 T cells was two times greater than the frequency
of total cytokine-producing CD4 T cells in the negative control
and greater than 0.05%. Background cytokine production in the
negative control of ICS assays was subtracted from each antigen-
stimulated condition. For phenotypic and polyfunctional analysis,
only individuals with positive T cell responses to Mtb antigens
(n = 12/18) and PPD (n = 18/18) were included, as shown in
Table 1.
Bacteriological assessment of sputum acid-fast bacilli
smear and sputum culture
Sputum culture and MGIT DST were performed at the time of
admission to Sizwe Hospital and monthly thereafter, as part of
routine care to monitor the progress of treatment. In addition,
sputum smear microscopy was performed regularly to monitor the
presence of acid-fast bacilli (AFB) under direct fluorescent
microscopy by auramine stain. The results of routine microbio-
logical testing were utilized for this study. Sputum culture
conversion was defined as two consecutive negative sputum
culture results, separated by at least 30 days, with no subsequent
culture positive results. Time to culture conversion was determined
from the interval between the initiation of treatment for MDR-TB
at Sizwe Hospital and the date of collection of the sputum
specimen that yielded the first negative culture result, in
accordance with the South African National Guidelines for
Treatment of MDR-TB [21]. For the purposes of this study, the
time of admission to Sizwe Hospital for treatment of MDR-TB
and enrollment into the study are defined as baseline.
Statistical Analysis
Statistical testing was performed using GraphPad Prism v5.0a
software (GraphPad Prism software version 5 (Software MacKiev,
GraphPad, San Diego, CA). Data were expressed as median
values and analyzed by the use of nonparametric statistics.
Statistical significance was determined using Mann-Whitney,
Wilcoxon Paired t test, or Kruskal-Wallis ANOVA using Dunn’s
test for multiple comparisons. All tests were two-tailed, and a value
of p,0.05 was considered statistically significant. Statistical
analysis of T cell multi-cytokine expression differences between
groups, represented in pie-chart format, was made using a non-
parametric partial permutation method within SPICE [23]. The
relationship between the proportions of activated CD4 T cells and
time to sputum culture negative was assessed by either Pearson or
Spearman rank correlations, depending on whether data was
normally distributed and passed the Shapiro-Wilk normality test.
Receiver operator characteristics (ROC) and area under the curve
(AUC) were used to assess the predictive nature of CD4 subsets
with time to culture conversion.
Results
Cohort Characteristics
For analysis, patients were assigned into two groups based on
sputum culture (SC) results at the time of initiating treatment for
Figure 1. Comparison of the frequencies of Mtb, PPD and mitogen responsive CD4 T cells at baseline between patients who were
sputum culture (SC) negative or positive. (A) The magnitude of antigen-specific CD4 T cells expressing any of the 3 cytokines measured (i.e.
IFNc, IL2 and TNFa) and expressed as a % of total CD4 population. Open symbols represent SC negative patients (n = 6) and solid symbols represent
SC positive patients (n = 12). The horizontal line shows the median. Non-Parametric Mann-Whitney t-test was used for statistical comparisons. (B)
Representative flow cytometry dot plots showing the level of expression of IFNc, IL2 and TNFa after no stimulation (NS), Mtb peptides, PPD and
mitogen (MITO) in the whole blood ICS assay. The numbers in the quadrant represent the frequency of cells expressing each cytokine. The gating
strategy is shown in Figure S1.
doi:10.1371/journal.pone.0102178.g001
Mycobacteria-Specific CD4 T Cells in MDR-TB Clearance
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MDR-TB at Sizwe Hospital (baseline): SC positive and SC
negative. Table 1 shows the microbiological characteristics and TB
history of each patient prior to and at the time of hospital
admission and enrollment. Six patients were negative for AFB
smear and Mtb culture (SC negative) at baseline, but all were SC
positive at a median of 56 (IQR: 42–72) days prior to admission
(Table S1). Three of these patients (50%) had a prior history of
TB, 5 (83%) were on treatment for drug susceptible TB at the time
of admission and one was TB treatment naı¨ve. These patients had
a median CXR disease score of 5.50 (IQR: 1.00–6.00), and one
(17%) had cavitary disease at baseline. All of the 12 patients who
were SC positive on admission had a prior history of TB; eight
(67%) were on treatment for drug susceptible TB, two (17%) were
receiving second line drugs and two (17%) were not on TB
treatment. Sputum smear results at baseline ranged from negative
to AFB+++ (Table S1). Among these patients, the median CXR
disease score was 7.00 (IQR: 7.00–9.00), and nine (75%) had
cavitary disease on admission. Thus, in general, the patients who
were SC positive at baseline had a more extensive history of TB
and showed more severe clinical signs of disease. While the
majority of patients in both groups were on TB chemotherapy at
the start of the study, the SC negative patients were apparently
more responsive to the suboptimal drug regimen, leading to lower
bacillary load at baseline. Among the 12 SC positive patients, the
time to first negative sputum Mtb culture ranged from 32–177
days (Table 1). One patient (#3) was discharged after the first
negative culture result and did not have any further results
recorded, so that culture conversion could not be confirmed. At
baseline, all patients exhibited a positive response to PPD and
mitogen, as measured by whole blood intracellular cytokine
staining, and 12/18 showed detectable responses to Mtb antigens.
Frequencies of Mtb- and PPD-specific CD4 T cells cannot
distinguish patients who are SC positive and SC negative
at baseline
We first compared the overall frequencies of total Mtb- and/or
PPD-specific CD4 T cells expressing IFNc, TNFa or IL2 in
patients who were SC positive and SC negative at baseline
(Figure 1A). While there was no difference in the magnitude of
total mycobacteria-specific CD4 T cells, mitogen responding CD4
T cells were approximately 3.5 fold higher (p = 0.01) in patients
who were SC negative at baseline than those who were SC positive
(median: 8.7% [IQR: 3.9–11.8] and 2.5% [IQR: 1.7–3.5],
respectively). As shown in Table 1, four patients who were SC
Figure 2. Comparison of the polyfunctional profiles of Mtb-, PPD- and Mito-specific CD4 T cells at baseline between patients who
were sputum culture (SC) negative or positive. Pie and Bar charts showing the proportion (A) and relative frequency (B) of each cytokine
combination after Mtb, PPD and mitogen (Mito) stimulation. The colors of the pies correspond to the permutation color grid at the foot of 2B, where
this corresponds to the proportional frequency of cytokine-expressing combinations. Twelve of 18 patients responded in the ICS assay to the Mtb
antigen cocktail: 4 SC negative and 8 SC positive. All 18 patients responded to PPD and Mito stimulations: 6 SC negative and 12 SC positive for each
ICS stimulus. Statistical analysis of T cell multi-cytokine expression differences between groups, represented in the pie charts in Figure A, was made
using a non-parametric partial permutation method within SPICE [23] and differences between antigen-specific CD4 T cells in Figure B using the
student’s t-test.
doi:10.1371/journal.pone.0102178.g002
Mycobacteria-Specific CD4 T Cells in MDR-TB Clearance
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negative and eight patients who were SC positive at baseline
showed detectable cytokine expression (Figure 1A). Figure 1B
shows representative dot-plots of CD4 T cells expressing IFNc,
TNFa and IL2 in response to Mtb, PPD and mitogen stimulation
in a patient responding to both antigens.
Using Boolean gating to examine multiple cytokine combina-
tions at the single cell level (i.e. polyfunctional responses), we found
no differences in the polyfunctional capacity between Mtb, and
PPD responsive CD4 T cells. The proportion of patients who
responded in a polyfunctional manner to Mtb antigens (n = 12
patients), PPD and mitogen (n = 18 patients) in the ICS assay are
shown in Figure 2A. On closer examination, the predominant
cytokine combinations in response to Mtb or PPD stimulation
were IFNc+IL2+TNFa+ (630% of total CD4 T cells) and
IFNc+IL22TNFa+ (620%). The proportions of these dual
expressing mycobacteria-specific CD4 T cells were significantly
higher in SC positive than SC negative patients (p = 0.013 for Mtb
and p = 0.014 for PPD, Figure 2B). The response to mitogen
stimulation was predominantly mono-functional (670%), with
IFNc2IL22TNFa+ (640%) being most prevalent.
Mtb- and PPD-specific CD4 T cells show a late
differentiated (LD) memory phenotype in patients who
are SC positive at baseline
We next evaluated the memory differentiation profiles of
mycobacteria-specific CD4 T cells at baseline. Using the
differentiation markers CD45RA and CD27, we were able to
discriminate four CD4 T cell populations. Figure 3A shows
representative plots of naı¨ve (CD45RA+CD27+), early differenti-
ated memory (ED: CD45RA2CD27+), late differentiated memory
(LD: CD45RA2CD272) and terminally differentiated cells (TD:
CD45RA+CD272). Figure 3B shows that there were significantly
higher proportions of ED Mtb- and PPD-specific CD4 T cells in
individuals who were SC negative compared to those who were
SC positive (p = 0.004 and p = 0.0012, respectively). Conversely,
there was a higher proportion of LD Mtb- and PPD-specific CD4
T cells in SC positive patients (p = 0.028 and p = 0.0017,
respectively). No difference in memory differentiation profiles in
mitogen responsive CD4 T cells was observed (Figure 3B).
Figure 3. Comparison of memory maturation and activation profiles of antigen-specific CD4 T cells at baseline between sputum
culture (SC) negative and positive individuals. (A) Representative overlay flow cytometry dot/density plots of TB-, PPD- and mitogen (mito)-
specific CD4 T cell subsets (red) onto total CD4 sub-population (grey) for an individual with positive SC (top panel) and negative SC (bottom panel).
Different CD4 subsets are shown as Naı¨ve, Early Differentiated memory (ED), Late Differentiated memory (LD) and Terminally Differentiated (TD). The
numbers in each quadrant represent the proportion of antigen-specific cell within each subset (red dots). (B) Proportion of naı¨ve, ED, LD and TD
subsets in Mtb (4 SC negative and 8 SC positive), PPD (6 SC negative and 12 SC positive) and mitogen (6 SC negative and 12 SC positive) responsive
CD4 T cells. The open symbols represent patients who were SC negative and solid symbols represent patients who were SC positive. The horizontal
line corresponds to the median. Non-Parametric Mann-Whitney t-test was used for statistical comparisons. (C) Representative flow cytometry dot-
plots of the level of expression of Ki-67 and HLA-DR within PPD-specific CD4 T cell in a SC negative and a SC positive representative patient. The
numbers represent the proportion of cells co-expressing Ki-67 and HLA-DR. (D) Proportion of activated cells (co-expressing Ki-67 and HLA-DR) in Mtb
(4 SC negative and 8 SC positive), PPD (6 SC negative and 12 SC positive) and mitogen (6 SC negative and 12 SC positive) responsive CD4 T cells. Non-
Parametric Mann-Whitney t-test was used for statistical comparisons.
doi:10.1371/journal.pone.0102178.g003
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Activated and proliferation-competent Mtb- and PPD-
specific CD4 T memory cells are enriched in patients who
are SC positive at baseline
We compared the relative proportions of activated (HLA-DR+)
and proliferating (Ki67+) antigen-specific CD4 T cells in SC
negative and SC positive patients. Figure 3C shows representative
flow plots of PPD-specific CD4 T cells co-expressing Ki67 and
HLA-DR. Overall, the percentages of Mtb, PPD and mitogen
responsive Ki67+HLA-DR+ CD4 T cells were higher in SC
positive than SC negative patients (p = 0.004, p = 0.0009 and
p = 0.001, respectively; Figure 3D). When these double positive
CD4 T cells were gated (Figure 3C) and analyzed for expression of
naı¨ve and memory markers, both Mtb and PPD-specific
Ki67+HLA-DR+ CD4 T cells fell mainly within the LD memory
sub-population (Figure S2). Taken together, these data show that
distinct subsets of Mtb and PPD-specific CD4 T cells were able to
differentiate between SC negative and SC positive patients, and
the characteristics of these cells were the dual expression of TNFa
and IFNc, markers of LD stage memory or co-expression of HLA-
DR and Ki67.
Polyfunctionality of Mtb- and PPD-specific CD4 T cells
increased during the course of MDR-TB treatment
We then analyzed the evolution of mycobacteria-specific CD4
T cell subsets over the course of treatment in patients who were
SC positive on admission. Figure 4 shows the proportion of CD4 T
cells producing cytokines (IFNc, IL2 and TNFa) in response to
Mtb (Figure 4A) or PPD (Figure 4B) stimulation and changes in
these over time of chemotherapy. There was a progressive increase
in the polyfunctional capacity of both Mtb- and PPD-specific CD4
T cells (p = 0.017 and p = 0.0087, respectively) between the time of
admission and 6 months of treatment. In particular, the
proportion of triple-expressing IFNc+IL2+TNFa+ cells increased
from baseline to 6 months of treatment (p = 0.048 and p = 0.014
for Mtb and PPD responses, respectively). In addition, the dual
expressing population IFNc+IL22TNFa+ of Mtb and PPD-specific
CD4 T cells, which discriminated between sputum culture status
prior to treatment, significantly decreased within the first 2 months
of chemotherapy (p = 0.035 and p = 0.001 in response to Mtb and
PPD stimulation respectively) in patients who were SC positive at
baseline. There was no change in the polyfunctional nature of
mitogen responsive CD4 T cells (data not shown). While there was
no significant change to the overall frequency of mycobacteria-
specific CD4 T cells over time, the proportion of mitogen
responsive CD4 T cells significantly increased as early as 2 months
after the initiation of treatment (p = 0.002, Figure S3). Of note, the
increase in polyfunctional PPD-specific CD4 T cells at 6 months of
chemotherapy was observed in both ED and LD memory
populations (p = 0.009 and p = 0.006, respectively), and the LD
population was more polyfunctional than the ED memory subset
at 6 months (p = 0.001) (data not shown). Additionally, there was a
trend toward an increased proportion of ED cells over time of
treatment (Figure S4). These findings suggest that polyfunction-
ality and the stage of memory differentiation are not necessarily
associated. Collectively, these data show that effective therapy
leads to an increase in the polyfunctional nature of Mtb- and PPD-
specific CD4 T cells, regardless of memory status, and induces an
increased responsiveness to mitogen stimulation.
Decreased activation status of Mtb and PPD-specific CD4
T cells during treatment
To correlate changes in the proportions of activated and
proliferating mycobacteria-specific CD4 T cells with sputum
culture conversion, we determined the frequencies of Ki-67+HLA-
DR+ antigen-specific CD4 T cells over time. Figure 5A shows
representative dot plots, where the frequency of Ki-67+HLA-DR+
Figure 4. Evolution of the polyfunctional profile of Mtb- and PPD-specific CD4 T cells over time of TB chemotherapy in individuals
with positive sputum culture (SC) at baseline. Pie and Bar charts showing changes in the proportions and relative frequency of multi-cytokine
combinations after Mtb (A) and PPD (B) stimulation over time from baseline (BL, pre-treatment), 2, 4 and 6 months (M) of treatment. The color codes
in the pies correspond to the permutation color blocks at the foot of each bar chart. Eight of the patients who were SC positive at baseline and
responded to the Mtb antigen cocktail are shown in A. Twelve of the patients who were SC positive and responded to PPD stimulations and are
shown in B. Statistical analysis of the changes in CD4+ T cell multi-cytokine proportions over time, represented in the pie charts, was made using the
non-parametric partial permutation method within SPICE [23] and differences between the relative frequency of antigen-specific CD4+ T cells over
time, represented by the solid colored symbols in the bar chart, was assessed using the Wilcoxon T-test.
doi:10.1371/journal.pone.0102178.g004
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PPD-specific CD4 T cells diminished from 20% at baseline to
1.3% at 6 months of treatment. Consolidation of these data in
Figure 5B shows a rapid and significant reduction in the
proportion of Ki-67+HLA-DR+ Mtb- and PPD-specific CD4 T
cells within the first 2 months of treatment (p = 0.03 and p = 0.002,
respectively). No significant changes in the activation profile of
mitogen responsive CD4 T cells were observed over time.
Collectively, these results show that TB treatment induced rapid
changes leading to lower activation and proliferation of mycobac-
teria-specific CD4 T cells.
The proportion of activated mycobacteria-specific CD4 T
cells at baseline can predict the time to sputum culture
conversion
Longer time to sputum culture conversion (Table 1) was
significantly associated with a greater proportion of PPD-specific
Ki-67+HLA-DR+ CD4 T cells present at baseline (r = 0.68,
p = 0.025, data not shown). Mtb-specific associations were not
significant, although the trend was similar. Receiver operating
characteristic (ROC) curves show that the proportion of Ki-
67+HLA-DR+ CD4 T cells at baseline was predictive of time to
sputum culture conversion. This was the case when using either
PPD or combined PPD/Mtb-specific Ki-67+ CD4 T cells (for
PPD, AUC of 0.833 (p = 0.068); 95% ci: 0.57–1.098 and for Mtb/
PPD, AUC of 0.80; p = 0.027, Figure 6). Of note, neither the
frequencies, memory maturation profile nor polyfunctional
capacity of mycobacteria-specific CD4 T cells had any significant
predictive value to time of culture conversion (data not shown).
Discussion
We interrogated the phenotypic and functional profile of
mycobacteria-specific CD4 T cells in the blood of patients who
were sputum culture (SC) positive and SC negative on admission.
We hypothesized that a sub-population of these cells may be used
as markers of bacillary (antigen) load. Two subsets of late
differentiated memory and activated proliferating (Ki67+HLA-
DR+) antigen-specific CD4 T cells were identified that could
discriminate between patients with and without sputum culturable
bacilli. The activated sub-population of cells in the blood, whether
Mtb- or PPD-specific, appeared to mirror antigen load in the
lungs, and the baseline frequency significantly associated with the
time taken to achieve culture conversion. This was further
supported by the finding that the lowest frequencies of activated
Figure 5. Changes in the proportion of antigen-specific CD4 T cells co-expressing HLA-DR and Ki67 over time of chemotherapy in
individuals with positive SC at baseline. (A) Representative flow cytometry dot-plots showing the level of Ki-67 and HLA-DR co-expression
within PPD-specific CD4 T cells at baseline (BL), 2, 4 and 6 months (M) of treatment. The numbers in the quadrants represent the proportion of
antigen-specific CD4 T cells co-expressing Ki-67 and HLA-DR. (B) Proportion of activated (Ki-67+HLA-DR+) cells within Mtb, PPD and mitogen
responsive CD4 T cells over time (months). The statistical differences were assessed using Wilcoxon matched pairs test.
doi:10.1371/journal.pone.0102178.g005
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and proliferating mycobacteria-specific CD4 T cells were found in
six of the eighteen patients who were SC negative upon
enrollment. Although MDR-TB was detectable in these partici-
pants, they were most likely responsive to standard chemotherapy,
and this was reflected in the lowest detectable frequency of
mycobacteria-specific proliferating CD4 T cells in these patients.
These data also suggest that our findings may also be applicable to
patients with drug susceptible TB.
This study highlights four main findings, each of which
underlines the immune response to TB, but can also be applied
to assess sputum culture status or to monitor the efficacy of TB
treatment. The first finding was that the degree of mycobacteria-
specific CD4 T cell memory differentiation is associated with
bacillary load, as indicated by SC positivity, and is in agreement
with the results of studies of patients with drug susceptible TB.
These reports describe higher LD mycobacterial-specific CD4 T
cells relative to ED cells in TB patients who were smear or culture
positive prior to treatment and a shift to relatively higher
proportions of ED CD4 T with treatment or in individuals with
cured TB [15,24]. In addition, patients with persistently active TB
disease who remained SC positive after 6 months of treatment
were shown to have low frequencies of antigen-specific
CD27+CD4 T cells [25]. Collectively, these results suggest that
chronically high levels of mycobacterial antigens in active TB lead
to the accumulation of LD memory cells.
Our second finding was a larger proportion of proliferating (as
measured by Ki-67) and activated (as measured by HLA-DR) Mtb
and PPD-specific CD4 T cells in patients who were SC positive
compared to SC negative patients. Up-regulation of the nuclear
protein, Ki-67, occurs when cells leave the G0 (resting) phase and
enter into the G1, S, G2 and M phases of the cell cycle [26]. The
increased expression of Ki-67, along with HLA-DR co-expression,
supports the presence of systemically activated T cells in patients
with SC positive TB and likely elevated bacillary load. Our results
appear to be in contrast with a study by Day et al, showing higher
proportions of activated proliferating CD4 T cells in individuals
with latent TB infection and in patients following TB treatment
compared to those with active TB disease [27]. However, in this
study, proliferative capacity was evaluated in Oregon Green
stained peripheral blood mononuclear cells (PBMC) following 6
days of antigen stimulation. In contrast, our results were obtained
from whole blood that was stimulated for 12 hours and stained for
the nuclear marker Ki-67, which we consider to be more
representative of the in vivo condition. In particular, it may be
expected that over 6 days, some CD4+ T cell populations may die
in the assay and those that respond and proliferate will likely be
central memory cells. We speculate that persistently high levels of
TB antigens are enough to drive activation of mycobacteria-
specific CD4 T cells to proliferation and propose that these cells
reflect antigen load in the host and therefore represent potentially
useful biomarkers of the extent of Mtb infection.
The third finding of this study was that polyfunctional
mycobacteria-specific CD4 T cells increased over time of TB
treatment. This is consistent with other reports from studies of
patients with drug susceptible TB [28]. In particular, the decline in
IFNc+IL22TNFa+ CD4 T cells coincident with an increased
population of IFNc+IL2+TNFa+ CD4 T cells is in agreement with
Day et al [27], who investigated changes in relation to bacillary
load, as defined by sputum smear acid-fast bacilli (AFB), during
treatment. These results may indicate that higher mycobacterial
load is associated with impaired IL2 production, which recovers
with treatment and bacillary clearance [29]. This hypothesis is
supported by several cross-sectional studies showing a higher
proportion of mycobacteria-specific IFN+IL22TNF+ or IFN-
g+IL22 CD4 T cells or lower IL2+ CD4 T cells in patients with
active TB than in patients after successful treatment [24,30–32].
The discordance of our data with one study showing that
polyfunctionality diminished upon TB treatment [33] may be
explained by differences in the assay conditions, such as the use of
PBMCs instead of whole blood, varying sources of serum, and
different antigens used in ex vivo stimulations [34]. We also found
that the increased polyfunctionality of CD4 T cells was not
necessarily linked with the emergence of ED CD4 T cells, as
polyfunctional CD4 T cells increased in both ED and LD
populations with response to treatment. Moreover, PPD-specific
LD cells were more polyfunctional after 6 months of chemother-
apy than ED cells, suggesting that memory differentiation and the
ability to express multiple cytokines were not associated. While the
increased polyfunctional CD4 T cell population, seen as a
protective phenotype in multiple experimental studies [35–38],
may indicate improved immunity, as suggested by Harari et al
[28], this may merely reflect a homeostatic response to lowered
mycobacterial antigen load.
Our fourth finding was the reduced frequency of activated
proliferating mycobacteria-specific CD4 T cells with bacillary
clearance and that baseline activation was predictive of time to
culture conversion. We hypothesize that, as bacterial burden is
cleared with antibiotic treatment, there is less antigenic stimulation
and immunity shifts to a more responsive state. This is consistent
with the observed increase in polyfunctionality and was reflected
in a trend toward an increased proportion of ED cells over time of
treatment (Figure S4). A similar association between antigen load
and T cell subsets has been described in the context of HIV viral
load during early infection [39] and in response to anti-retroviral
treatment [40]. To test this hypothesis, a validation cohort would
need to be analyzed.
It is important to note that the present study is a pilot involving
a small number of patients, which requires validation through a
larger cohort study. While the specific analytic approach used in
this study is not practical for wider application, identification of a
subset of cells that provides a robust predictor of response to TB
treatment can form a foundation for developing a simpler assay.
Figure 6. ROC curve analysis of mycobacteria-specific Ki-
67+HLA-DR+ CD4 T cells with time to sputum culture conver-
sion. Receiver Operating Characteristic curve for the proportion of
mycobacteria-specific Ki-67+HLA-DR+ CD4 T cells at baseline with the
time to sputum clearance. The area under the curve (AUC), p-value and
95% confidence interval (c.i.) are shown on the graph. The dotted line
represents an AUC of 0.5, which would depict a random test.
doi:10.1371/journal.pone.0102178.g006
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Nonetheless, the association between mycobacteria-specific T cell
activation and SC positivity and response to treatment is robust,
and, if confirmed, could be highly useful in advancing our
understanding of T cell biomarkers in TB treatment.
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Figure S1 Gating strategy for the measurement of
antigen-specific CD4 T cells.
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Figure S2 Comparison of the memory maturation
profiles of activated (i.e. Ki67+HLA-DR+: +/+) versus
non-activated (i.e. Ki672HLA-DR2: 2/2) mytobacteria-
specific CD4 T cells in individuals with a positive SC at
baseline. (A) A representative flow cytometry dot plot of Ki67
and HLA-DR expression levels in PPD-specific CD4 T cells. Cells
negative for Ki67 and HLA-DR (non-activated, 2/2) and
positive for both (activated, +/+) are shown in the bottom left
and top right quadrants. (B) Distribution of activated (+/+) and
non-activated (2/2) PPD- and Mtb-specific CD4 T cells within
distinct CD4 subpopulations. Horizontal lines depict the median
values and non-Parametric Mann-Whitney t-test was used for
statistical comparisons.
(PDF)
Figure S3 Comparison of the frequencies of antigen-
specific CD4 T cells in response to Mtb, PPD and Mito
stimulation in individuals with a positive SC at baseline,
and over time of chemotherapy. The magnitude of antigen-
specific CD4 T cells expressing any of the 4 cytokines measured
(i.e. IFNc, IL2 and TNFa) is expressed as a % of total CD4
population. Each line represents an individual. Measurements
have been performed at baseline (0), 2, 4 and 6 months after the
initiation of TB-MDR therapy. The statistical differences were
assessed using Wilcoxon matched paired test.
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Figure S4 Changes in memory maturation profile of
antigen-specific CD4 T cells over time of chemotherapy
in individuals with positive SC at baseline. (A) Represen-
tative flow cytometry dot-plots of the level of expression of
CD45RA and CD27 within PPD-specific CD4 T cells at baseline
(0), 2, 4 and 6 months after TB-MDR therapy initiation. The
numbers in the quadrants represent the proportion of antigen-
specific CD4 T within each sub-population. (B) Proportion of early
differentiated (ED) cells within Mtb, PPD and mitogen responsive
CD4 T cells over time (months). The statistical differences were
assessed using Wilcoxon matched paired test.
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Table S1 Diagnosis and treatment characteristics of
patients enrolled into the study, showing the days
between admission and most recent positive sputum
culture, method of diagnosis (drug susceptibility testing
(DST), Line Probe Assay (LPA) PCR bands signifying R
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drug cocktail regimens.
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